Annuncio • May 06
Centrum Launches Newly Reformulated Adults 50+ Complete Multivitamin with Clinically Shown Cognitive Benefits Centrum announced the launch of Centrum Adults 50+ Complete Multivitamin, reformulated to support the changing nutritional and health needs of adults aged 50 and over, including memory and cognitive health.Developed with a comprehensive blend of essential vitamins and minerals, the formula supports areas of health as nutritional needs change with age. It includes Vitamin C and Zinc to support immune health, B vitamins to help with energy metabolism, Magnesium for muscle function, and Vitamin D and Calcium to help maintain bone strength.There is recent science-backed evidence showing that multivitamins can be beneficial for cognitive health. Several randomized clinical trials using Centrum* from Harvard Medical Schooland its affiliated Hospitals, demonstrated memory and neurological benefits. Centrum Adults 50+ Complete Multivitamin is clinically shown to support memory and brain health, reinforcing the brand’s long-standing commitment to evidence-based innovation. Annuncio • Apr 28
Haleon Announces the Appointment of Richard Mansoas as Us Chief Marketing Officer, Effective April 27, 2026 Haleon announced the appointment of Richard Mansoas as US Chief Marketing Officer, effective April 27, 2026. In this role, Manso will partner closely with CEO, US & President, North America Nathalie Gerschtein and the US leadership team to accelerate Haleon’s evolution into a more agile, consumer-centric organization. Manso will lead Haleon’s integrated US marketing organization, advancing how the company connects with consumers in the moments where health decisions actually happen. He will work across categories and global teams to integrate data, technology and human insight, strengthening Haleon’s ability to deliver more personalized, transparent and relevant health experiences. His appointment comes at a time of significant transformation in consumer health, as individuals take a more active, self-directed role in managing their well-being and increasingly expect seamless, personalized, and on-demand experiences. In this environment, marketing is emerging as a critical driver of trust - shaping how companies show up across every touchpoint in everyday life. At Haleon, Manso will focus on strengthening modern marketing capabilities across the US business—driving growth within and across categories, and advancing priority areas including Medicare Advantage OTC, GLP-1, and emerging platforms such as Women’s and Pediatric Health. His role will also support Haleon’s broader ambition to build a more connected, insight-led marketing ecosystem that reflects how consumers engage with health today. Manso brings experience across marketing, technology and digital transformation, most recently serving in senior leadership roles at Google, where he led large-scale B2B marketing programs and helped drive adoption of data and AI-enabled marketing solutions. His background also includes leadership roles spanning consumer brands and digital strategy. Manso will report directly to Nathalie and serve as a member of the US Leadership Team. Board Change • Apr 08
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Non-Executive Director Matt Shattock was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Annuncio • Mar 16
Haleon plc, Annual General Meeting, Apr 29, 2026 Haleon plc, Annual General Meeting, Apr 29, 2026. Annuncio • Mar 13
Haleon plc (LSE:HLN) announces an Equity Buyback for £500 million worth of its shares. Haleon plc (LSE:HLN) announces a share repurchase program. Under the the company, the Company has entered into an irrevocable agreement with HSBC Bank plc to repurchase £500 million worth of its share. The purpose of the program is to reduce the Company's share capital. All shares purchased by the company will be cancelled. The program will end no later than August 19, 2026. Annuncio • Mar 12
Parodontax, the Gum Expert Brand from Haleon launches New Gum Strengthen and Protect Toothpaste and Mouthwash Parodontax, the gum expert brand from Haleon, has launched NEW parodontax Gum Strengthen & Protect Toothpaste and Mouthwash with Hyaluronic Acid, a daily oral care innovation formulated to strengthen the gum seal where gums and teeth meet for long-lasting gum protection. Parodontax expands its gum care portfolio with NEW Gum Strengthen & Protect Toothpaste and Mouthwash with Hyaluronic Acid. Gum Strengthen & Protect is formulated to strengthen the gum seal for long-lasting gum protection with continued twice daily use, kill plaque bacteria along the gumline to support a stronger, tighter seal between gums and teeth with continued twice daily use, and support healthy gum hydration. Enhanced with Hyaluronic Acid as part of everyday oral care across two format options: Fresh Mint Toothpaste and Icy Mint Mouthwash. The new line is enhanced with hyaluronic acid, a well-known ingredient across skincare and wellness. In the toothpaste, hyaluronic acid contributes to foaming action during brushing. In the mouthwash, it provides extra freshness. Together, the formulas help support a hydrated, healthier-feeling gum experience as part of everyday oral care. The parodontax Gum Strengthen & Protect with Hyaluronic Acid line is available in toothpaste and mouthwash formats and can be used separately or together as part of a daily gum care routine. Fresh Mint Toothpaste — Enhanced with hyaluronic acid for foaming action, this fluoride toothpaste strengthens the gum seal where gums and teeth meet, helping protect against gum problems returning with continued twice-daily use. Icy Mint Mouthwash — Formulated with hyaluronic acid for extra freshness, this alcohol-free mouthwash kills plaque bacteria along the gumline to support a stronger, tighter seal between gums and teeth. Parodontax Gum Strengthen & Protect is now available at major retailers nationwide, including Amazon, Walmart, CVS, and Target. Always follow the label. If gum problems persist, consult a dental professional. Annuncio • Feb 26
Haleon plc to Report First Half, 2026 Results on Jul 30, 2026 Haleon plc announced that they will report first half, 2026 results on Jul 30, 2026 Annuncio • Feb 25
Haleon plc Proposes Final Ordinary Dividend for Fiscal Year 2025, Payable on 14 May 2026 Haleon plc announced that reflecting the strength of FCF generation during the year, alongside strong organic operating profit growth, the Board is proposing a 2025 total dividend of 7.1 pence per ordinary share which represents a payout ratio of approximately 38% of 2025 adjusted earnings (2024: 37%). This includes a final dividend of 4.9 pence per ordinary share. Subject to shareholder approval, the final dividend will be paid on 14 May 2026 to holders of ordinary shares and US American Depositary Shares (ADS) on the register as of 10 April 2026 (the record date). The ex-dividend date for ordinary shares will be 9 April 2026 and for US American Depositary Shares (ADS) 10 April 2026. For ordinary shareholders wishing to participate in the Dividend Reinvestment Programme (DRIP), the election deadline will be 24 April 2026. Annuncio • Feb 11
Sensodyne Launches Sensodyne Clinical Repair Sensodyne unveils Clinical Repair, the brand's newest toothpaste option for sensitive teeth. Clinical Repair: Starts to repair sensitive areas of teeth after 60 seconds for clinically proven long-lasting relief. With twice daily brushing, Clinical Repair generates a protective layer that restrengthens with every use - protecting against sensitivity returning. Designed to target and strengthen enamel, addressing sensitivity at the source. Developed with a science-backed formula that delivers clinical efficacy with a clean, refreshing feel and an enjoyably minty brushing experience across two options: Whiten & Shine: A cool, arctic mint blend of peppermint and spearmint; Fresh Clean: Rich, refreshing mix of peppermint and eucalyptus.oth sensitivity affects millions of adults and can make everyday moments - from enjoying hot drinks to savings cold treats - uncomfortable or painful. Powered by a scientifically backed formula, Sensodyne Clinical Repair starts to repair sensitive areas of teeth After 60 seconds, forming a protective layer that restregthens with every use to deliver clinically proven, long-lasting relief from sensitivity. Innovative Repair Technology, Backed by Science: Sensodyne Clinical Repair features a formula that stays stable until brushing begins, when it's activated by saliva. With twice-daily brushing, this layer restrengthens with every using, protecting against sensitivity returning, all without changing every day brushing routine. In clinical studies, Sensodyne Clinical Repair created a protective layer that was harder and offered more complete coverage than two leading competitors, raising the bar in sensitivity repair. Two Options Designed for Everyday Oral Care Needs: Sensodyne Clinical Repair is designed to fit seamlessly into daily routines, helping people protect sensitive teeth while delivering cleaning and whitening benefits. The toothpaste is available in two refreshing options, now in a new blue color: Sensodyne Clinical Repair Whiten & Shine: Formulated for people who want sensitivity relief and a brighter smile. Whiten & Shine provides repair-focused sensitivity relief alongside superior whitening from stain removal. A cool, arctic mint blends of peppermint and spearmins leaves the mouth feeling fresh and polished. Sensodyne Clinical Repair Fresh Clean: Designed for those who want a deep clean and long-lasting freshness. Fresh Clean delivers gentle, repair-focused sensitivity relief with cleaning action through stain removal, featuring a rich, foaming formula and a refreshing blend of peppermint and eucallyptus for a just-brushed feeling that lasts. Built for Modern Routines: As personal care routines become more intentional and performance-driven, Sensodyne Clinical Repair isdesigned to fit seamlessly into everyday brushing, delivering fast, reliable protection without compromise. Its clinically proven repair technology provides substantial sensitivity relief in as little as three days, while continuing to strengthen protection with ongoing use. Pricing & Availability: Sensodyne Clinical Repair are now available at leading retailers, such as Amazon, Walmart, and Target, and nationwide soon, with an MSRP of $8.99. Annuncio • Jan 09
Haleon Announces Executive Changes Haleon announced on 09 January 2026 the appointment of Kedar Lele as president, India subcontinent. Lele moves from Castrol India, where he was managing director, and has succeeded former Haleon India chief Navneet Saluja, who retired in October 2025. Lele will also join the Haleon Executive Team, the company's global leadership entity. Saluja retired after 17 years at Haleon, where he held diverse leadership roles in functions across sales and strategy, as well as overseeing Horlicks' divestment to HUL, followed by setting up Haleon as an independent entity in India. Lele brings over 25 years of experience across various sectors, including Fast Moving Consumer Goods (FMCG), advertising, digital innovation, and the automotive industry. He spent almost a year and a half at Castrol and has also worked with Kimberly-Clark Lever Ltd. as a marketing executive in the past. He holds an MBA in Strategic Marketing and Operations from the Indian School of Business and a postgraduate diploma in Marketing Communications from MICA, Ahmedabad, Gujarat. Additionally, he serves on the board of TVS Automobile Solutions and previously served as the Vice President at the Foreign Investors Chamber of Commerce & Industry, Bangladesh. Annuncio • Jan 08
Haleon plc Announces Evolution of Its Operating Model to Drive Growth and Agility Haleon plc has announced that it is evolving its operating model in support of its Win as One strategy to drive its growth, productivity and culture agenda, as set out at its Capital Markets Day in May 2025. These changes are expected to be implemented by mid-2026. Haleon is creating six Operating Units (OUs) to enable the Company to capitalise on the significant growth opportunities in its key markets, with each OU responsible for delivering business performance through the execution of Haleon's category strategies. The current EMEA & LatAm region will be separated into three constituent OUs: Latin America (LatAm), Middle East and Africa (MEA) and Europe. Recognising the strength of Haleon's business in India Subcontinent (ISC) and the opportunities for growth, ISC will become its own OU, separate from Asia Pacific. Haleon's North America OU remains unchanged. Annuncio • Dec 15
Haleon plc Announces Board and Committee Changes, with Effect from 1 January 2026 Haleon plc announced that Alan Stewart will succeed Vindi Banga as Senior Independent Director ("SID"), upon Vindi's appointment as Chair with effect from 1 January 2026. Alan Stewart joined the Board as a Non-Executive Director and Chair of the Audit & Risk Committee in September 2024. Alan will remain Chair of the Audit & Risk Committee and a member of the Remuneration Committee, Nominations & Governance Committee and Environmental & Social Sustainability Committee following his appointment as Senior Independent Director. In accordance with the UK Corporate Governance Code 2024, Vindi will step down as a member of the Audit & Risk Committee effective 31 December 2025. Vindi will also step down as a member of the Remuneration Committee effective 31 December 2025 and be appointed Chair of the Nominations & Governance Committee effective 1 January 2026. Annuncio • Nov 10
Haleon plc Announces Board Changes Haleon plc announced the resignation of Sir Dave Lewis as Chair and appointment of Vindi Banga. Dave Lewis will step down as Chair of the Board and as a Director of the Company on 31 December 2025 in order to pursue a new executive role. The Board announced the appointment of Vindi Banga as Chair to succeed Dave with effect from 1 January 2026. Vindi has served as Senior Independent Director on the Haleon Board since the Company's listing in 2022. The Board was unanimous in its appointment of Vindi given his wealth of global corporate and commercial leadership experience. He has an extensive track record of delivering outstanding performance in highly competitive global consumer-focused businesses and a deep understanding of operating across developed and emerging markets. He spent 33 years at Unilever plc, where he was also CEO and Chair of Hindustan Unilever Ltd, one of India's largest listed companies, and was also responsible for Global Home & Personal Care, Foods and Ice Cream and a member of the Unilever Executive Board. Vindi also has extensive international Board experience. He is currently Chair of UK Government Investments Limited (UKGI) and has previously served as Senior Independent Director at GSK and Marks and Spencer plc. Vindi is a partner at CD&R, a leading private investment firm where he has chaired and served on the boards of several of the firm's portfolio companies. He is Chair of Council of Imperial College London. Vindi's remuneration and the appointment of a successor as Senior Independent Director will be announced in due course and before Vindi's appointment as Chair takes effect. Annuncio • Oct 30
Haleon plc Reiterates Earnings Guidance for the Fiscal Year 2025 Haleon plc Reiterated earnings guidance for the fiscal year 2025. For the year, the company now reiterating organic revenue growth to be around 3.5% assuming a normal cold and flu season and high-single digit organic operating profit growth. Declared Dividend • Aug 03
First half dividend of UK£0.022 announced Shareholders will receive a dividend of UK£0.022. Ex-date: 14th August 2025 Payment date: 18th September 2025 Dividend yield will be 1.8%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is well covered by both earnings (40% earnings payout ratio) and cash flows (28% cash payout ratio). The dividend has increased by an average of 66% per year over the past 2 years and payments have been stable during that time. EPS is expected to grow by 21% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Aug 01
First half 2025 earnings released: EPS: UK£0.089 (vs UK£0.079 in 1H 2024) First half 2025 results: EPS: UK£0.089 (up from UK£0.079 in 1H 2024). Revenue: UK£5.48b (down 3.8% from 1H 2024). Net income: UK£806.0m (up 11% from 1H 2024). Profit margin: 15% (up from 13% in 1H 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 5% per year. Annuncio • Jul 30
Haleon plc Appoints Bláthnaid Bergin to the Audit & Risk Committee and Matt Shattock to the Environmental & Social Sustainability Committee with Effect from 30 July 2025 Haleon plc announced the appointments of Bláthnaid Bergin to the Audit & Risk Committee and Matt Shattock to the Environmental & Social Sustainability Committee with effect from 30 July 2025. Annuncio • Jun 27
Haleon plc (LSE:HLN) completed the acquisition of 12% stake in Tianjin TSKF Pharmaceutical Co. Ltd from Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329). Haleon plc (LSE:HLN) agreed to acquire 12% stake in Tianjin TSKF Pharmaceutical Co. Ltd from Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329) for CNY 1.6 billion on April 15, 2025. A cash consideration of CNY 1.62 billion will be paid by Haleon plc. As part of consideration, CNY 1.62 billion is paid towards common equity of Tianjin TSKF Pharmaceutical Co. Ltd. Upon completion, Tianjin TSKF Pharmaceutical Co. Ltd will become a wholly owned subsidiary of Haleon plc (LSE:HLN). The acquisition is expected to be funded through a combination of Haleon plc's existing cash resources and new third-party CNY denominated debt.
The transaction is subject to approval by regulatory board / committee and approval of offer by target shareholders. The expected completion of the transaction is within the period from April 15, 2025 to July 15, 2025. As of June 3, 2025, Extraordinary general meeting of Tianjin Pharmaceutical Da Ren Tang Group Corporation will be held on June 9, 2025 at 2:00 p.m.
Haleon plc (LSE:HLN) completed the acquisition of 12% stake in Tianjin TSKF Pharmaceutical Co. Ltd from Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited on June 27, 2025. Annuncio • Jun 24
Haleon plc Announces Executive Changes Haleon plc announced the appointment of Carl Haney as Chief Research & Development Officer. Carl will join Haleon on 1 August 2025. This appointment follows Franck Riot deciding to leave Haleon after six years in the business. Carl joins Haleon from the Estée Lauder Companies Inc. where he has spent 13 years as Executive Vice President, Global Innovation and Research and Development. Carl previously spent over 20 years at P&G across Home, Health and Beauty Care. Annuncio • May 26
Sensodyne Launches New Premium Clinical White Toothpaste to Brighten Canadians' Smile Day Sensodyne has released its new, premium Clinical White toothpaste. Scientifically developed and clinically proven to whiten teeth up to two shades whiter. Clinical White offers 24/7 sensitivity protection in an enamel-safe formula. Free from hydrogen peroxide, a trigger that may cause sensitivity, it lifts stains in hard-to-reach places, polishes for a smoother, shinier finish, and helps prevent future staining. With National Smile Day taking place this Saturday, May 31, Sensodyne's Clinical White arrives just in time offering an affordable, effective solution for those seeking a brighter smile without the pain. Gentle enough for daily use, it's the perfect companion for coffee lovers, red wine enthusiasts, and anyone who wants to smile with confidence, because people shouldn't have to choose between a white smile and a comfortable one. Upcoming Dividend • Apr 17
Upcoming dividend of UK£0.046 per share Eligible shareholders must have bought the stock before 24 April 2025. Payment date: 05 June 2025. Payout ratio is a comfortable 42% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of German dividend payers (4.6%). Higher than average of industry peers (1.5%). Annuncio • Apr 15
Haleon plc (LSE:HLN) agreed to acquire 12% stake in Tianjin TSKF Pharmaceutical Co. Ltd from Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329) for CNY 1.6 billion . Haleon plc (LSE:HLN) agreed to acquire 12% stake in Tianjin TSKF Pharmaceutical Co. Ltd from Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329) for CNY 1.6 billion on April 15, 2025. A cash consideration of CNY 1.62 billion will be paid by Haleon plc. As part of consideration, CNY 1.62 billion is paid towards common equity of Tianjin TSKF Pharmaceutical Co. Ltd. Upon completion, Tianjin TSKF Pharmaceutical Co. Ltd will become a wholly owned subsidiary of Haleon plc (LSE:HLN).
The transaction is subject to approval by regulatory board / committee and approval of offer by target shareholders. The expected completion of the transaction is July 15, 2025. Annuncio • Mar 22
Haleon plc, Annual General Meeting, May 28, 2025 Haleon plc, Annual General Meeting, May 28, 2025. Recent Insider Transactions • Mar 19
CEO & Executive Director recently sold €3.5m worth of stock On the 14th of March, Brian McNamara sold around 755k shares on-market at roughly €4.59 per share. This transaction amounted to 34% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Brian's only on-market trade for the last 12 months. Annuncio • Feb 28
Haleon plc to Report First Half, 2025 Results on Jul 31, 2025 Haleon plc announced that they will report first half, 2025 results on Jul 31, 2025 Reported Earnings • Feb 27
Full year 2024 earnings released: EPS: UK£0.16 (vs UK£0.11 in FY 2023) Full year 2024 results: EPS: UK£0.16 (up from UK£0.11 in FY 2023). Revenue: UK£11.2b (flat on FY 2023). Net income: UK£1.44b (up 38% from FY 2023). Profit margin: 13% (up from 9.3% in FY 2023). Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Annuncio • Feb 26
Bryan Supran (Non-Executive Director and Representative of Pfizer Inc.) Steps Down from the Board of Haleon plc Haleon plc announces the following change to the Board. Following the reduction ofPfizer Inc.'s shareholding in Haleon plc below 10%, and in line with the Pfizer Relationship Agreement with Haleon plc, Bryan Supran, Non-Executive Director and representative of Pfizer Inc., stepped down from the Board on 25 February 2025. Annuncio • Jan 15
Pfizer Intends to Sell Approximately 700 Million Ordinary Shares in Haleon Pfizer Inc. (NYSE:PFE) announced that it intends to sell approximately 700 million ordinary shares in Haleon plc (LSE:HLN), representing approximately 7.7% of Haleon's issued share capital. This announcement is not and does not constitute an offer to sell and there will be no public offering of the Sale Shares in any jurisdiction. There will be no sale of any Ordinary Shares in the form of American depositary shares in Haleon. The price per Sale Share will be determined by way of an accelerated book building process to institutional investors. The book building period will commence immediately following this announcement and may close at any time on short notice. The completion of the book building process and the results of the Offering, including the number of Sale Shares to be sold and the price per Sale Share, will be announced as soon as practicable thereafter. Pfizer will receive all of the net proceeds from the Offering, subject to customary closing conditions. No Ordinary Shares are being sold or issued by Haleon in the Offering, and Haleon will not receive any of the net proceeds from the Offering. Completion of the Offering is expected to reduce Pfizer's interest in Haleon from approximately 15.0% to approximately 7.3% of Haleon's issued ordinary shares with voting rights. J.P. Morgan and Morgan Stanley are acting as joint global coordinators and joint bookrunners (the "Joint Global Coordinators"), HSBC, BNP PARIBAS, Mizuho and UBS are acting as joint bookrunners and BofA Securities, Deutsche Numis, Goldman Sachs International and Loop Capital Markets are acting as co-managers for the Offering. Pfizer has undertaken to the Managers not to transfer or dispose of any of its remaining equity securities in Haleon for 60 days from the date of settlement of the Offering, subject to certain exceptions and waiver by the Joint Global Coordinators. Annuncio • Dec 05
Haleon plc Announces Board Changes Haleon plc announced the following changes to the Board. Following the reduction of Pfizer Inc.'s shareholding in Haleon plc below 20%, and in line with the Pfizer Relationship Agreement with Haleon plc, David Denton, Non-Executive Director and representative of Pfizer Inc., stepped down from the Board on 4 December 2024. Bláthnaid Bergin has been appointed as an independent Non-Executive Director and will join the Haleon Board on 24 February 2025. Bláthnaid Bergin brings financial leadership and strategic planning experience from a variety of consumer-facing businesses. Bláthnaid is currently the Chief Financial Officer of J Sainsbury plc, where she has played a pivotal role in driving the company's financial strategy and operational efficiency initiatives. Prior to joining Sainsbury's, Bláthnaid held senior finance leadership and international positions at Aviva, RSA and GE working across Europe, Asia and Australia. She is a Chartered Accountant. Bláthnaid was previously Non-Executive Director, Chair of the Audit Committee and Senior Independent Director for Artemis Alpha Investment Trust. Reported Earnings • Nov 01
Third quarter 2024 earnings released: EPS: UK£0.053 (vs UK£0.04 in 3Q 2023) Third quarter 2024 results: EPS: UK£0.053 (up from UK£0.04 in 3Q 2023). Revenue: UK£2.78b (flat on 3Q 2023). Net income: UK£485.0m (up 33% from 3Q 2023). Profit margin: 17% (up from 13% in 3Q 2023). Revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Personal Products industry in Europe. Annuncio • Oct 03
Haleon plc (LSE:HLN) commences an Equity Buyback Plan for 455,701,825 shares, representing 4.99% of its issued share capital., under the authorization approved on May 8, 2024. Haleon plc (LSE:HLN) commences share repurchases on October 1, 2024, under the program mandated by the shareholders in the Annual General Meeting held on May 8, 2024. As per the mandate, the company will repurchase up to 455,701,825 shares, representing 4.99% of it's outstanding shares. Any off-market purchases by way of standalone purchase shall be at a fixed 2.5% discount to the most recent close of market price of the Company’s ordinary shares on the London Stock Exchange. If an off-market purchase is made in conjunction with a Share Offering, the price payable by the Company to Pfizer (or its nominee(s)) will be equal to the price at which each ordinary share is to be sold to the public in the Share Offering (as determined through a book building process or otherwise). The repurchase authorization will expire at the conclusion of the next annual general meeting of the Company, or June 30, 2025. As of April 3, 2024, the company had 9,132,301,104 shares in issue and no shares in treasury.
On July 29, 2024, the company announced that it has entered into an agreement with Pfizer Inc. to repurchase 60,526,315 ordinary shares,for £230 million (approximately $308 million) worth of its shares. The purchase price per Ordinary Share to be paid by Haleon plc in the Share Buyback will be equal to the offering price per Sale Share in the Offering i.e. £3.80 per share. Of the repurchased shares 30,161,278 ordinary shares worth approximately £114.6 million in aggregate which will be cancelled and 30,365,037 ordinary shares worth approximately £115.4 million in aggregate that will be held as treasury shares for the purposes of satisfying Haleon's obligations under its existing employee share plans in 2025. The deal will close at the same time as the secondary offering of Pfizer, or as soon as reasonably practicable following, the settlement of the Offering, which is expected to be completed on October 3, 2024. Annuncio • Oct 02
Pfizer Intends to Sell About 540 Million Ordinary Shares in Haleon Pfizer Inc. (NYSE:PFE) said it intends to sell around 540 million ordinary shares in British consumer-healthcare business Haleon plc (LSE:HLN), or about 5.9% of the company's issued share capital. The pharmaceutical giant said that the price per share will be determined by way of an accelerated bookbuilding process to institutional investors. Pfizer will receive all net proceeds from the offering, it said. In a separate statement, Haleon said it agreed to make an off-market purchase of approximately $307.7 million worth of its ordinary shares from Pfizer. Annuncio • Oct 01
Dr. Reddy'S Laboratories S.A. completed the acquisition of Northstar Switzerland SARL from Haleon plc (LSE:HLN). Dr. Reddy'S Laboratories S.A. has entered into an agreement to acquire Northstar Switzerland SARL from Haleon plc (LSE:HLN) for £500 million on June 26, 2024. Under the terms of agreement, Dr. Reddy’s Laboratories SA will pay an upfront cash consideration of £458 million and additional performance-based contingent cash payments of up to £42 million in CY 2025 and CY 2026. As part of consideration, £500 million is paid towards assets of Nicotine replacement therapy (“NRT”) business of Haleon plc. The portfolio consists of brands including Nicotinell, Nicabate, Habitrol and Thrive available in gum, lozenge and patch forms across over 30 markets. This divestment will allow Haleon to exit the NRT category outside of the US and will reduce complexity across the business allowing increased focus on strategic growth areas. The acquisition will enable the Company to gain access to a global OTC anchor brand and is seen as a potential vehicle to build the Company’s global consumer healthcare OTC business. Prior to completion of the transaction, Haleon Group will transfer assets related to the NRT portfolio into Northstar Switzerland and/or its fully-owned step-down subsidiaries. As described above, the Company will own 100% shareholding in Northstar Switzerland on the completion of the transaction. Upon closing of the transaction, Dr. Reddy’s will acquire the NRT business in all countries outside of the United States. However, operations will transition to Dr. Reddy’s in a phased approach to ensure successful integration of the business. The financial results of the NRT business represented net revenue of £217 million for the financial year ended 31 December 2023.
The closing of the transaction is subject to satisfactory completion of customary closing conditions including the applicable waiting periods under applicable merger control and transaction is expected to close by early Q4 of calendar year 2024. The proceeds from the transfer of inventory will be received within the same timeframe. Use of the net cash proceeds will be determined in line with capital allocation priorities, including reducing leverage. Assuming completion of the transaction in early Q4 2024, this divestment is expected to dilute FY 2024 net revenue and adjusted operating profit by c. 0.5% and c. 1% respectively. Alan Montgomery, Siddhartha Shukla, Dean Wanjala and Arina Abgaryan of Herbert Smith Freehills LLP acted as legal advisor to Dr. Reddy'S Laboratories S.A. Greenhill & Co. International LLP acted as financial advisor to Haleon plc.
Dr. Reddy'S Laboratories S.A. completed the acquisition of Northstar Switzerland SARL from Haleon plc (LSE:HLN) on June 26, 2024. Annuncio • Sep 03
Haleon Announces the Launch of Eroxon®?, the First and Only Fda Cleared Otc Gel for Erectile Dysfunction, Available for U.S. Pre Order Without A Prescription Haleon announced that Eroxon is now available for pre-order in the United States through Amazon and will be available at most major retailers in October 2024. Eroxon is clinically proven to help men get an erection within 10 minutes to foster physical intimacy (individual results may vary). The treatment stimulates nerve endings in the penis to help men with ED get and maintain an erection during sex. Given existing prescription solutions may take up to an hour to work (based on labels), Eroxon addresses a significant unmet need for men experiencing ED. Clinical study results show that Eroxon is safe and effective in men with ED. While ED can be caused by underlying physical conditions, psychological challenges such as stress, anxiety, depression, and other mental health issues may also contribute to ED, especially in younger men. Eroxon aims to help men with ED enhanceacy and connection in their relationships, fostering closer and more fulfilling partnerships. How to use Eroxon: Unscrew cap. Pierce the tube seal with top of cap. Squeeze tube firmly to empty all the contents onto finger(s), which will provide the correct dose. Massage the gel onto the head of user's penis for about 15 seconds. If User are uncircumcised, gently pull user's foreskin back as far as comfortable before applying the gel. It may take a few attempts to achieve the desired effect. User can apply the gel, or user's partner can apply the gel to user's penis as part of foreplay. In a clinical study, partners applied the product for the male as part of foreplay, which resulted in better outcomes. Annuncio • Aug 04
Haleon plc (LSE:HLN) commences an Equity Buyback Plan for 913,000,000 shares, representing 10% of its issued share capital, under the authorization approved on May 8, 2024. Haleon plc (LSE:HLN) commences share repurchases on August 2, 2024, under the program mandated by the shareholders in the Annual General Meeting held on May 8, 2024. As per the mandate, the company will repurchase up to 913,000,000 shares, representing 10% of it's outstanding shares. The shares will be repurchased at the minimum price which may be paid for each such share is the nominal value of such share and the maximum price which may be paid for each such share is the higher of an amount equal to 5% above the average of the middle market quotations for an ordinary share as derived from the Daily Official List of the London Stock Exchange for the five business days immediately preceding the day on which the relevant share is purchased and the higher of the price of the last independent trade and the highest current independent purchase bid on the trading venues where the purchase is carried out. Any shares purchased may be held as treasury shares with a view to possible re-issue at a future date, be used to satisfy awards under share incentive arrangements or cancelled. The repurchase authorization will expire at the conclusion of the next annual general meeting of the Company, or June 30, 2025. As of April 3, 2024, the company had 9,132,301,104 shares in issue.
On August 1, 2024, the company announced a share repurchase program. Under the program, the company will repurchase £185 million worth of shares. The purpose of the Buyback program is to reduce share capital and is in line with the Company's capital allocation priorities. All Shares purchased by the Company under the Buyback program will be cancelled. The Buyback program commences today and will end no later than December 31, 2024. Declared Dividend • Aug 04
First half dividend of UK£0.02 announced Shareholders will receive a dividend of UK£0.02. Ex-date: 15th August 2024 Payment date: 19th September 2024 Dividend yield will be 1.6%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is covered by both earnings (52% earnings payout ratio) and cash flows (22% cash payout ratio). The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. EPS is expected to grow by 43% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Aug 02
Second quarter 2024 earnings released: EPS: UK£0.033 (vs UK£0.032 in 2Q 2023) Second quarter 2024 results: EPS: UK£0.033 (up from UK£0.032 in 2Q 2023). Revenue: UK£2.78b (flat on 2Q 2023). Net income: UK£303.0m (up 1.7% from 2Q 2023). Profit margin: 11% (in line with 2Q 2023). Revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Personal Products industry in Europe. Annuncio • Aug 01
Haleon plc to Report Fiscal Year 2024 Results on Mar 05, 2025 Haleon plc announced that they will report fiscal year 2024 results on Mar 05, 2025 Annuncio • Jun 27
Dr. Reddy'S Laboratories S.A. signed a definitive agreement to acquire Northstar Switzerland SARL from Haleon plc (LSE:HLN) for £500 million. Dr. Reddy'S Laboratories S.A. has entered into an agreement to acquire Northstar Switzerland SARL from Haleon plc (LSE:HLN) for £500 million on June 26, 2024. Under the terms of agreement, Dr. Reddy’s Laboratories SA will pay an upfront cash consideration of £458 million and additional performance-based contingent cash payments of up to £42 million in CY 2025 and CY 2026. As part of consideration, £500 million is paid towards assets of Nicotine replacement therapy (“NRT”) business of Haleon plc. The portfolio consists of brands including Nicotinell, Nicabate, Habitrol and Thrive available in gum, lozenge and patch forms across over 30 markets. This divestment will allow Haleon to exit the NRT category outside of the US and will reduce complexity across the business allowing increased focus on strategic growth areas. The acquisition will enable the Company to gain access to a global OTC anchor brand and is seen as a potential vehicle to build the Company’s global consumer healthcare OTC business. Prior to completion of the transaction, Haleon Group will transfer assets related to the NRT portfolio into Northstar Switzerland and/or its fully-owned step-down subsidiaries. As described above, the Company will own 100% shareholding in Northstar Switzerland on the completion of the transaction. Upon closing of the transaction, Dr. Reddy’s will acquire the NRT business in all countries outside of the United States. However, operations will transition to Dr. Reddy’s in a phased approach to ensure successful integration of the business. The financial results of the NRT business represented net revenue of £217 million for the financial year ended 31 December 2023.The closing of the transaction is subject to satisfactory completion of customary closing conditions including the applicable waiting periods under applicable merger control and transaction is expected to close by early Q4 of calendar year 2024. The proceeds from the transfer of inventory will be received within the same timeframe. Use of the net cash proceeds will be determined in line with capital allocation priorities, including reducing leverage. Assuming completion of the transaction in early Q4 2024, this divestment is expected to dilute FY 2024 net revenue and adjusted operating profit by c. 0.5% and c. 1% respectively. Annuncio • May 17
GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon GSK plc (LSE:GSK) announced that it intends to sell approximately 385 million ordinary shares in Haleon plc (LSE:HLN), equivalent to approximately 4.2% of Haleon's issued share capital and representing GSK's entire shareholding in Haleon. Following the successful demerger and premium listing of Haleon plc (‘Haleon’) as announced on 18 July 2022, GSK initially retained a 12.94% stake in Haleon. As a result of the disposals announced on 12 May 2023, 6 October 2023 and 16 January 2024, GSK has since sold a total of 810 million ordinary shares in Haleon, reducing its stake in Haleon to approximately 4.2%. The disposal announced on May 16, 2024 will be conducted through a placing of ordinary shares in Haleon to institutional investors (the ‘Offering’). The offer price will be determined by means of an accelerated bookbuild offering process which is to start immediately. A further announcement will be made following completion of the bookbuild and pricing of the Offering. GSK has entered into a secondary block trade agreement with BofA Securities (‘BofA’) and Goldman Sachs International (‘Goldman Sachs’) under which BofA and Goldman Sachs have been appointed to act as the Joint Global Coordinators of the Offering. Reported Earnings • May 02
First quarter 2024 earnings released: EPS: UK£0.046 (vs UK£0.042 in 1Q 2023) First quarter 2024 results: EPS: UK£0.046 (up from UK£0.042 in 1Q 2023). Revenue: UK£2.92b (down 2.2% from 1Q 2023). Net income: UK£423.0m (up 8.7% from 1Q 2023). Profit margin: 14% (up from 13% in 1Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 4.2% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Personal Products industry in Europe. Annuncio • May 01
Haleon plc Announces Directorate Change Haleon plc announced that following Deirdre Mahlan's appointment as President, Chief Executive Officer and Chairperson of the Board of The Duckhorn Portfolio Inc., Deirdre will be stepping down from her role as Non-Executive Director and Chair of the Audit & Risk Committee of Haleon. Deirdre has agreed to continue as Non-Executive Director and Chair of the Audit & Risk Committee of Haleon until a successor has been identified. Buy Or Sell Opportunity • Mar 19
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 2.9% to €3.83. The fair value is estimated to be €3.19, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years. Earnings per share has declined by 5.1%. For the next 3 years, revenue is forecast to grow by 3.7% per annum. Earnings are also forecast to grow by 11% per annum over the same time period. Annuncio • Mar 11
Sensodyne Introduces New Triple Action Formula: 'Sensitivity Gum & Enamel' Sensodyne launched Sensodyne Sensitivity Gum & Enamel, a clinically proven, ground-breaking innovation with a specialized triple mode of action formula that provides long-lasting sensitivity relief, helps restore gum health, and strengthens enamel in two weeks. Its innovative Micro Foam technology effectively delivers the active ingredient (Stannous Fluoride) in hard-to-reach areas between teeth and along the gumline. Oral health problems are considered to be largely preventable through effective oral hygiene, yet their prevalence remains high. In Malaysia, 94% of Malaysian adults have gum problems, 71% suffer from tooth sensitivity, and nearly 46% experience yellowing of teeth, which may be due to the loss of enamel, according to a 2021 Kantar study. These findings highlight a significant consumer need for solutions addressing a range of oral health concerns in Malaysia. Sensodyne in teeth is primarily caused by gum issues and enamel erosion. Enamel is the outer most protective layer of the tooth which may weaken with time due to acids in common food and beverages, whereas gum problems stem from plaque bacteria accumulation. Sensodyne is continuing its movement of #BetterOralCareNation to raise oral health awareness across Malaysia and motivate Malaysians to prioritize their oral health for healthier gums and teeth. The campaign includes a capturing television commercial, eye-catching outdoor advertising, engaging on-ground activities, and innovative content across Sensodyne Malaysia's website, social media channels, and traditional media platforms. By collaborating with healthcare professionals, social media creators, and influencers, Sensodyne aims to deliver channel-relevant reliable information. The campaign officially launched on 1st March, with the first event taking place on 7th March at Sunway Velocity Mall in Kuala Lumpur, with free dental check-up (sensitivity, gum and enamel tests). As part of the engagement activities, the popular #BetterOralCareNation Anthem is brought back on social media to inspire Malaysians to improve their oral health awareness and practices. Sensodyne Sensitivity Gum& Enamel toothpaste can be found in pharmacies, dental clinics, minimarkets, markets, and hypermarkets across Malaysia. Upcoming Dividend • Mar 07
Upcoming dividend of UK£0.042 per share Eligible shareholders must have bought the stock before 14 March 2024. Payment date: 16 May 2024. Payout ratio is a comfortable 53% and this is well supported by cash flows. Trailing yield: 2.6%. Lower than top quartile of German dividend payers (5.1%). Higher than average of industry peers (2.2%). Declared Dividend • Mar 03
Final dividend of UK£0.042 announced Shareholders will receive a dividend of UK£0.042. Ex-date: 14th March 2024 Payment date: 16th May 2024 Dividend yield will be 1.6%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is covered by both earnings (53% earnings payout ratio) and cash flows (39% cash payout ratio). The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. EPS is expected to grow by 71% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Annuncio • Mar 02
Haleon plc, Annual General Meeting, May 08, 2024 Haleon plc, Annual General Meeting, May 08, 2024. Annuncio • Mar 01
Haleon plc to Report First Half, 2024 Results on Aug 01, 2024 Haleon plc announced that they will report first half, 2024 results on Aug 01, 2024 Reported Earnings • Mar 01
Full year 2023 earnings released: EPS: UK£0.11 (vs UK£0.12 in FY 2022) Full year 2023 results: EPS: UK£0.11 (down from UK£0.12 in FY 2022). Revenue: UK£11.3b (up 4.1% from FY 2022). Net income: UK£1.05b (down 1.0% from FY 2022). Profit margin: 9.3% (in line with FY 2022). Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 5.4% growth forecast for the Personal Products industry in Europe. Annuncio • Mar 01
Haleon plc Proposes Final Dividend for Fiscal Year 2023, Payable on 16 May 2024 Haleon plc announced that Reflecting the strength of the free cash flow and the progress in deleveraging since the demerger the Board is proposing a fiscal year 2023 total dividend of 6.0 pence per ordinary share which represents a pay-out ratio of approximately 35% of Fiscal Year 2023 adjusted earnings (ahead of prior commentary that this would represent an approximately 30% pay out). This includes a final dividend of 4.2 pence per ordinary share. Subject to shareholder approval, the final dividend will be paid on 16 May 2024 to holders of ordinary shares and US American Depositary Shares (ADS) on the register as of 15 March 2024 (the record date). The ex-dividend date is 14 March 2024. For ordinary shareholders wishing to participate in the Dividend Reinvestment Programme (DRIP), the election deadline for the DRIP is 17 April 2024. Annuncio • Feb 29
Haleon plc Provides Earnings Guidance for the Fiscal Year 2024 Haleon plc provided earnings guidance for the fiscal year 2024. For the full year, the company expects organic revenue growth of 4% to 6% and organic operating profit growth ahead of organic revenue growth. Reported Earnings • Nov 03
Third quarter 2023 earnings released: EPS: UK£0.04 (vs UK£0.037 in 3Q 2022) Third quarter 2023 results: EPS: UK£0.04 (up from UK£0.037 in 3Q 2022). Revenue: UK£2.80b (down 3.3% from 3Q 2022). Net income: UK£365.0m (up 5.8% from 3Q 2022). Profit margin: 13% (up from 12% in 3Q 2022). Revenue is forecast to grow 4.2% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Personal Products industry in Europe. Annuncio • Nov 02
Haleon plc Provides Earnings Guidance for the Fiscal Year 2023 Haleon plc provided earnings guidance for the fiscal year 2023. For the year, the company expects organic revenue growth to be between 7% to 8%. Board Change • Oct 20
High number of new and inexperienced directors There are 11 new directors who have joined the board in the last 3 years. The company's board is composed of: 11 new directors. No experienced directors. No highly experienced directors. CEO & Executive Director Brian McNamara is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. 
